- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
What is SepXiris<sup>®</sup> (AN69ST) ?
-
- Asano Kengo
- Intensive Care Unit, Department of Anesthesiology, Jikei University School of Medicine
-
- Uchino Shigehiko
- Intensive Care Unit, Department of Anesthesiology, Jikei University School of Medicine
Bibliographic Information
- Other Title
-
- AN69ST(セプザイリス<sup>®</sup>)とは何か?
Search this article
Description
<p>SepXiris® is a membrane for continuous renal replacement therapy composed of AN69ST (surface-treated polyacrylonitrile). For its high cytokine adsorption ability, SepXiris®has been approved in Japan since 2014 to treat severe sepsis or septic shock patients. However, approval does not necessarily guarantee clinical effects. Therefore, we have reviewed published studies on the effect of SepXiris®, and evaluated the validity of its use in clinical practice. Our literature search found that most studies for SepXiris® on sepsis were animal experiments or in-vitro studies, and that clinical studies targeting sepsis were extremely limited. Additionally, there are many problems in the clinical studies that hamper showing any clinical benefit of SepXiris®. In conclusion, we have found that there is no evidence to support the use of SepXiris® for sepsis.</p>
Journal
-
- Journal of Japan Society for Surgical Infection
-
Journal of Japan Society for Surgical Infection 15 (3), 238-241, 2018-06-30
Japan Society for Surgical Infection
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282763047188736
-
- NII Article ID
- 130007482330
-
- ISSN
- 24340103
- 13495755
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- CiNii Articles
-
- Abstract License Flag
- Disallowed